Anti-NGF antibodies and methods thereof
The present disclosure encompasses novel anti-NGF antibodies, antigen binding proteins and polynucleotides encoding the same. The disclosure further provides use of the novel antibodies, antigen binding proteins and/or nucleotide of the invention for the treatment and/or prevention of NGF related disorders, particularly in for the management of pain.
1. An anti-Nerve Growth Factor (NGF) antibody comprising a variable light chain comprising the amino acid sequence of SEQ ID NO. 7 and a variable heavy chain comprising the amino acid sequence of SEQ ID NO. 8.
2. The antibody of claim 1 wherein said antibody inhibits the binding of NGF to the TrkA receptor.
3. The antibody of claim 1 wherein said antibody reduces or eliminates pain.
4. The antibody of claim 1 , wherein said antibody is a monoclonal antibody.
5. The antibody of claim 4 wherein said monoclonal antibody is a canine monoclonal antibody.
6. A pharmaceutical or veterinary composition comprising a therapeutically effective amount of the antibody of claim 1 and a pharmaceutically acceptable carrier.